Anti-aging peptide
Epitalon: what the human research actually shows
An anti-aging peptide built around a real pineal extract, with real Russian human data, and zero independent confirmation of any of it. I would not treat Epitalon as a proven longevity intervention in 2026.
Why I looked into this
Epitalon comes up in almost every longevity newsletter and biohacker group chat I pay attention to. The pitch is always the same three ideas: telomerase activation, melatonin normalization, and life extension. Sometimes the pitch comes with a dramatic figure attached, like a 4.1-fold reduction in mortality over six years in an elderly cohort.
Those claims made me skeptical enough to go read the actual papers instead of the writeups. This is what I found in the primary literature, what the record does and does not support, and where I think the gap between the pitch and the evidence is widest.
What Epitalon actually is
Epitalon, also spelled Epithalon, carries the laboratory code AEDG. It is a short synthetic peptide made of four amino acids: alanine, glutamate, aspartate, and glycine. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, building on work that began in the late Soviet era.
The synthetic tetrapeptide was designed from the amino acid composition of Epithalamin, a peptide extract from the pineal gland of cattle that had been studied in the Soviet Union since the 1970s as a proposed bioregulator of aging. In plain language: Epitalon is a four-amino-acid fragment intended to mimic the behavior of a longer natural pineal gland product. This distinction matters later, because most of the human research cited as evidence for Epitalon was actually done on Epithalamin, the extract, not on the synthetic fragment.
What the human research shows
Do published human trials exist?
Yes, published human studies exist. They are indexed on PubMed. You can read them.
But the honest answer needs a caveat that most writeups quietly drop. Nearly every human paper on Epitalon or Epithalamin comes from the same Russian research group that developed the compound. There is no Phase 2 or Phase 3 trial registered in the US or EU. There is no industry-sponsored human trial in the Western regulatory record. There is no independent replication of the longevity or mortality findings by a non-Russian group in the quarter-century since the main papers were published.
That is the cleanest way I can state the situation: the human evidence exists, and the human evidence is narrow.
What evidence actually exists?
The most-cited human studies are:
- Korkushko et al., Bulletin of Experimental Biology and Medicine, 2004: a melatonin circadian rhythm study in healthy elderly subjects. The authors reported that Epithalamin modulated pineal melatonin-producing function, raising nocturnal melatonin in subjects with low baseline pineal activity.
- Korkushko et al., 2006: a three-year comparative study in 79 coronary patients. The 39-patient intervention arm received six courses of Epithalamin over three years in addition to standard cardiac care. The authors reported normalized melatonin rhythm, improved metabolic markers, and reduced cardiovascular decline relative to the 40-patient control group.
- Khavinson and Morozov, Neuroendocrinology Letters, 2003: a six-to-eight year follow-up of 266 elderly subjects, some receiving Thymalin plus Epithalamin annually. The combined-treatment arm showed the 4.1-fold mortality reduction that gets quoted everywhere.
- Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011: a fifteen-year follow-up of the earlier cohort, continuing to show survival benefit in the treated group.
- Khavinson et al., 2002: a small retinitis pigmentosa case series in Russian patients, reporting a positive clinical effect in roughly 90 percent of eyes.
What the research does not show
The research does NOT show:
- That the synthetic tetrapeptide AEDG produces life extension in healthy adults. The longevity data primarily used Epithalamin, the full pineal extract, not the synthetic Epitalon that people actually buy.
- Any independent confirmation by a research group outside the Khavinson lab, in any country, in any setting.
- Any US or EU regulatory Phase 2 or Phase 3 safety data.
- Telomere extension in human blood. The telomerase activation data comes from in vitro cell line studies, not from human tissue samples from treated people.
- Safety or effect in young, healthy adults outside the elderly cohorts that were studied.
The 4.1-fold mortality reduction figure that circulates in longevity newsletters is real in the sense that it appears in a peer-reviewed journal. It also comes from an open-label study, run by the same group that developed the compound, in a combined-treatment arm that included a separate peptide, with 266 subjects across multiple arms. That is not the quality of evidence you would need to build a clinical recommendation.
Known safety signals in humans
I found no published large-scale safety data from independent human trials. The Russian trials generally describe the compound as well tolerated in elderly subjects, but none of that reporting meets the pharmacovigilance standards used for FDA-regulated products.
There is no published data on long-term cancer risk in humans, on reproductive effects, on interactions with common medications, or on any effect in young, healthy adults. Post-market adverse event reports are near-zero, but the formal surveillance system that would capture them is also near-zero. Absence of reports is not the same as absence of signal.
FDA and legal status in the US
The July 24, 2026 Pharmacy Compounding Advisory Committee meeting will consider whether Epitalon belongs on the 503A bulk drug substances list for the specific indication of insomnia, alongside DSIP and Emideltide on the same day. Advisory committee inclusion is not approval, and it is not compounding authorization. Even if the committee votes to recommend inclusion, FDA must propose a rule, take public comment, and finalize. Historically that process runs well over a year.
Nothing about Epitalon’s current legal or regulatory status changes as a result of the July meeting alone. The meeting is a signal about what the regulatory system is paying attention to, not a change in what is allowed.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Epitalon specifically
The specific source-safety problem with Epitalon is that essentially every research-use-only offering in the US is a compound with no US pharmacopoeia monograph, no independent identity testing standard, and no enforcement of what the label actually contains. What gets sold as “Epitalon” online may be the AEDG tetrapeptide, it may be a related pineal peptide, or it may be something else entirely that the manufacturer substituted for cost reasons.
A 2014 analytical paper in Pharmaceutical Technology and Drug Research documented Epitalon showing up as a mislabeled constituent in illegal pharmaceutical preparations, meaning people were receiving something sold as a cancer or anti-aging drug that chemically contained the wrong compound entirely. That kind of identity failure is not a rumor. It is in the literature.
Cost reality
Expect $50 to $150 for a single vial of material labeled “Epitalon” from a research-use-only supplier. A licensed 503A compounding pharmacy, if one were willing to compound it under physician supervision, would likely cost significantly more, with paperwork and clinical oversight attached.
Cost is not a reliable quality signal here. Cheaper material is usually a worse bet; expensive material may still be mislabeled. The only real quality signal is the one you will not get from a research-use-only vendor: independent identity and purity testing by a lab that is not owned by the seller.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license?
- Do you provide a certificate of analysis from a third-party lab, not in-house testing only?
- Do you require a valid prescription from a licensed clinician?
- Do you have a physical US address and a phone number I can verify by calling?
- Which peptide exactly is in this vial: the synthetic AEDG tetrapeptide, the Epithalamin extract, or a related pineal product? What identity test did you use to confirm it?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Epitalon. If I were going to try an anti-aging peptide today, it would not be Epitalon. Not because the evidence is zero, but because the evidence that exists is the lowest-quality kind of human evidence a serious reader can be offered: a single research group, a single country, no independent replication, and a four-decade pattern of the same lab publishing the same general finding in journals most American clinicians have never opened.
The 4.1-fold mortality reduction figure that circulates in the longevity community is real in the sense that it appears in print. It is also from 2003, from an open-label study, from one research group, in a combined-treatment arm that also contained Thymalin, a separate peptide. So even if you believed the number at face value, you could not attribute it to Epithalamin alone, let alone to the synthetic tetrapeptide that biohackers actually buy.
What does seem genuinely interesting to me is the narrow, specific finding that Epithalamin modulates melatonin rhythm in elderly people with blunted pineal function. That is mechanistically plausible, and it is a much smaller claim than “telomerase-activating longevity peptide.” If the discourse around this compound had been built around the smaller claim, it would be healthier.
For someone who is curious, I would read the Khavinson 2003 paper and the Korkushko 2004 melatonin paper yourself, not the writeups. For someone considering use, I would wait for the PCAC outcome and any independent Western trial before spending real money or taking real risk. For someone who has already decided to try it, the source-safety framework matters more here than for most peptides on this site.
Questions to ask your doctor
If you are considering Epitalon, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about the Russian research on Epitalon and Epithalamin. Are you familiar with any of it, and do you see a clinical reason a compound like this would be worth discussing in my specific situation?
- If I were to consider this compound, what baseline labs would you want to see first, and what would you want to re-check later?
- Given that essentially all published human data comes from one research group without independent replication, how would you weigh that in your clinical judgment?
- Do you know of a licensed 503A compounding pharmacy that you would be willing to work with on a supervised protocol, rather than me sourcing material independently?
- If I developed unusual symptoms while using a pineal-acting peptide (mood change, sleep pattern disruption, hormonal shifts), what should I do and who should I contact first?
- Is there a conventional or FDA-approved option that addresses whatever outcome I am hoping Epitalon would produce, that we should try or rule out first?
What to do next
Read the primary research
Start with Khavinson 2003 in Neuroendocrinology Letters and Korkushko 2004 on elderly melatonin rhythm. Read them yourself, not the writeups.
Open the primer →Wait for PCAC, bring the packet
The July 24, 2026 FDA review is the first substantive public signal on Epitalon outside the Khavinson group. Bring the visit-prep packet to your clinician.
Get the packet →Source-safety first, always
Identity and purity are genuinely unreliable for Epitalon in the research-use-only market. The 503A checklist matters more here than anywhere.
Open the checklist →Sources
- Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. “Effect of peptide preparation Epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people.” Bulletin of Experimental Biology and Medicine. 2004. PMID 15452611.
- Khavinson VKh, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters. 2003;24(3-4):233-240. PMID 14523363.
- Khavinson VKh, Kuznik BI, Ryzhak GA. “Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up.” Bulletin of Experimental Biology and Medicine. 2011. PMID 22451889.
- Khavinson VKh, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. “Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa.” Neuroendocrinology Letters. 2002. PMID 12195242.
- Nowicka-Bauer K et al. “Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties.” International Journal of Molecular Sciences. 2025. PMID 40141333.
- FDA Federal Register. “Pharmacy Compounding Advisory Committee, Notice of Meeting.” Docket FDA-2025-N-6895, published April 16, 2026. Federal Register notice.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
BPC-157
Under the same July FDA review. Zero published human trials, a mountain of rodent data, and a reader discourse that pretends that gap doesn’t exist.
Semax
Same Russian-research-heritage story as Epitalon. Under PCAC review the same day. Read alongside for a full picture of the July 24 meeting.
KPV
Third of the July-review peptides with essentially no human data at all. The 503A list is being asked to make decisions on three compounds with no Phase 2 trials.